Development of a HPLC method to determine 5-fluorouracil in plasma: application in pharmacokinetics and steady-state concentration monitoring

被引:25
作者
Pi, Chao [1 ,2 ]
Wei, Yunneng [3 ]
Yang, Hongru [4 ]
Zhou, Yang [3 ]
Fu, Junjiang [5 ]
Yang, Siyun [6 ]
Ye, Yun [1 ,3 ]
Zhao, Ling [3 ]
机构
[1] Luzhou Med Coll, Affiliated Hosp 1, Dept Pharm, Nanchong, Sichuan Provinc, Peoples R China
[2] Peoples Hosp Luzhou City, Dept Anus Intestines Colorectal Surg, Nanchong, Sichuan Provinc, Peoples R China
[3] Luzhou Med Coll, Sch Pharm, Dept Pharmaceut Sci, Nanchong, Sichuan Provinc, Peoples R China
[4] Luzhou Med Coll, Affiliated Hosp 1, Dept Oncol, Nanchong, Sichuan Provinc, Peoples R China
[5] Luzhou Med Coll, Res Ctr Preclin Med, Nanchong, Sichuan Provinc, Peoples R China
[6] Nanchong Cent Hosp, Dept Pharm, Nanchong, Sichuan Provinc, Peoples R China
基金
中国国家自然科学基金;
关键词
reverse-phase HPLC; 5-fluorouracil; pharmacokinetics; plasma concentration at steady state; colorectal cancer; ADVANCED COLORECTAL-CANCER; DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY; PROTRACTED VENOUS INFUSION; 1ST-LINE CHEMOTHERAPY; MONONUCLEAR-CELLS; PHASE-II; OXALIPLATIN; LEUCOVORIN; TOXICITY; CAPECITABINE;
D O I
10.5414/CP202120
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A simple, rapid and sensitive high-power liquid chromatographic (HPLC) method for analysis of 5-fluorouracil (5FU) in patient plasma was developed and validated to study clinical pharmacokinetics (PK). Plasma sample preparation was processed with ammonium acetate buffer (pH 3.5; 0.01M) followed by liquid-liquid extraction with isopropanol/ethyl acetate (15 : 85, v/v). Extraction recovery ranged from 87.55 to 95.26%. Separation was performed using a C18 column at 25 C with UV detection at 265 nm. The isocratic mobile phase composed of acetonitrile-ammonium acetate buffer (pH 3.5; 0.01M) (2.5 : 97.5 v/v) at a flow rate of 0.8 mL/min Retention time was less than 7 minutes. Standard curve was linear between 0.01 - 10 mu g/mL and 10 - 100 mu g/mL for plasma sample. The limit of quantification was 10 ng/mL. The intra- and inter-day precision was below 10% (RSD). The accuracy ranged from 85.24 to 104.14%. The analysis method is rapid because it needs neither time-consuming extraction procedures nor complex chromatographic condition. The method was successfully applied to access pharmacokinetics and plasma concentration at steady state (SSC) of 5-FU. The results showed the PK and SSC of 5-FU characterized by a large interpatient variability. To increase therapeutic response and reduce toxicity, we should optimize 5-FU dose by investigating PK behavior to obtain ideal SSC.
引用
收藏
页码:1093 / 1101
页数:9
相关论文
共 29 条
  • [1] Oxidative damage to guanine nucleosides following combination chemotherapy with 5-fluorouracil and oxaliplatin
    Afzal, Shoaib
    Jensen, Soren Astrup
    Sorensen, Jens Benn
    Henriksen, Trine
    Weimann, Allan
    Poulsen, Henrik Enghusen
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (02) : 301 - 307
  • [2] Oxaliplatin in Combination With Infusional 5-Fluorouracil as First-Line Chemotherapy for Elderly Patients With Metastatic Colorectal Cancer: A Phase II Study of the Spanish Cooperative Group for the Treatment of Digestive Tumors
    Benavides, Manuel
    Pericay, Carles
    Valladares-Ayerbes, Manuel
    Gil-Calle, Silvia
    Massuti, Bartomeu
    Aparicio, Jorge
    Duenas, Rosario
    Gonzalez-Flores, Encarna
    Carrato, Alfredo
    Marcuello, Eugenio
    Gomez, Auxiliadora
    Cabrera, Enrique
    Queralt, Bernardo
    Gomez, Ma Jose
    Guasch, Inmaculada
    Etxeberria, Arantxa
    Alfaro, Jordi
    Campos, Juan Manuel
    Reina, Juan Jose
    Aranda, Enrique
    [J]. CLINICAL COLORECTAL CANCER, 2012, 11 (03) : 200 - 206
  • [3] Boisdron-Celle M, 2012, PHARMACOGENOMICS, V13, P1437, DOI [10.2217/PGS.12.132, 10.2217/pgs.12.132]
  • [4] LC-MS/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients
    Buechel, Barbara
    Rhyn, Peter
    Schuerch, Stefan
    Buehr, Claudia
    Amstutz, Ursula
    Largiader, Carlo R.
    [J]. BIOMEDICAL CHROMATOGRAPHY, 2013, 27 (01) : 7 - 16
  • [5] Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients
    Cassidy, J.
    Saltz, L.
    Twelves, C.
    Van Cutsem, E.
    Hoff, P.
    Kang, Y.
    Saini, J. P.
    Gilberg, F.
    Cunningham, D.
    [J]. ANNALS OF ONCOLOGY, 2011, 22 (12) : 2604 - 2609
  • [6] Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients
    Coriat, Romain
    Mir, Olivier
    Cessot, Anatole
    Brezault, Catherine
    Ropert, Stanislas
    Durand, Jean-Philippe
    Cacheux, Wulfran
    Chaussade, Stanislas
    Goldwasser, Francois
    [J]. INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 376 - 381
  • [7] 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer
    Di Paolo, Antonello
    Lencioni, Monica
    Amatori, Feclerica
    Di Donato, Samantha
    Bocci, Guido
    Orlandini, Cinzia
    Lastella, Marianna
    Federici, Francesca
    Iannopollo, Mauro
    Falcone, Alfredo
    Ricci, Sergio
    Del Tacca, Mario
    Danesil, Romano
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (09) : 2749 - 2755
  • [8] Surface-enhanced Raman Spectral Measurements of 5-Fluorouracil in Saliva
    Farquharson, Stuart
    Gift, Alan
    Shende, Chetan
    Inscore, Frank
    Ordway, Beth
    Farquharson, Carl
    Murren, John
    [J]. MOLECULES, 2008, 13 (10): : 2608 - 2627
  • [9] Findlay MPN, 1996, ANN ONCOL, V7, P47
  • [10] FLEMING RA, 1992, CANCER RES, V52, P2899